SK pharmteco completes second facility for C&GT manufacturing in Europe

The second facility of Yposkesi, SK pharmteco's commercial viral vector manufacturing subsidiary for Cell and Gene Therapies in France, which completed construction recently [SK PHARMTECO]

SK pharmteco completed its second facility for Cell and Gene Therapies (C&GT) manufacturing in Europe, doubling its viral vector production capacity to 10,000 square meters (2.47 acres).

The second production site of Yposkesi, SK pharmteco's commercial viral vector manufacturing subsidiary for C&GT, is situated on its Genopole campus, the largest biotech cluster in France.

The newly completed site is a 5,000-sqaure-meter facility that meets the standards set by Good Manufacturing Practices guidelines of the United States and Europe. Together with the first production site, which is also located in the Genopole campus, Yposkesi became one of Europe's largest biomanufacturing facility for C&GT that spans 10,000 square meters.

The new site specializes in the production of Adeno-associated virus and Lentiviral Vector — the widely used viral vectors in the field of cell and gene therapies, spanning from clinical to commercial applications. Viral vectors are utilized as carriers, delivering genes into targeted cells and the entire body.

Operation of the second facility will begin in 2024.

According to the global research firm MarketsandMarkets, the global viral vector market, estimated at $5.5 billion in 2023 and forecast to reach $12.8 billion by 2028, is projected to increase by a compound annual growth rate of approximately 18 percent.

BY SEO JI-EUN [seo.jieun1@joongang.co.kr]